Sustained Lung Inflation and Pulmonary Mechanics in Preterm Infant

February 26, 2021 updated by: Mariarosa Colnaghi, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Evaluation of Pulmonary Mechanics in Preterm Infant Treated With Sustained Lung Inflation at Birth

Lung protection should start in the delivery room where, from the first breaths, the preterm infant can be helped to clear the lung fluid and to recruit alveolar spaces and establish the functional residual capacity (FRC). Sustained lung inflation (SLI) applied at birth in the delivery room has been demonstrated to lead to clearance of lung fluid and achievement of a precocious functional residual capacity (FRC) both in animal and human studies. SLI associated to an adequate positive end expiratory pressure (PEEP) may help the efficacy of the respiratory effort in lung of preterm infants at risk for respiratory distress syndrome (RDS) and reduce need of mechanical ventilation (MV).

Further studies are required to evaluate the clinical utility of this maneuver. The ability to monitor what happens to the lungs while applying different recruitment maneuvers in preterm infants would allow the definition of a procedure that allows optimal assistance to improve the FRC. One promising approach is provided by the forced oscillation technique (FOT). During forced oscillations, a small amplitude sinusoidal pressure stimulus is applied to the airway opening and the mechanical response of the respiratory system is studied by means of the total respiratory input impedance (Zin). Zin is a complex number that can be expressed as real part, called resistance (Rrs), and imaginary part, called reactance (Xrs). Particularly, it has been recently shown that Xrs measured at 5 Hz is very sensible to changes in the mechanics of lung periphery and provides accurate information about lung volume recruitment and derecruitment. The main purpose of this work is to apply FOT to the assessment of lung function in newborns submitted to SLI at birth. The investigators hypothesized that the application in the delivery room of the SLI in the preterm infant is effective in achieving a greater FRC and therefore a greater value of Xrs compared to a control group not treated with the SLI.

Study Overview

Study Type

Interventional

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 months to 8 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Gestational age (GA) at least 25 weeks but less than 36 completed weeks by best obstetrical estimate

Exclusion Criteria:

  • Refusal of antenatal informed consent
  • Known major anomalies, pulmonary hypoplasia
  • Severe perinatal suffering

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SLI group
In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room; the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.
Sustained lung inflation (SLI) will be performed with mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR <100 bpm).
Other Names:
  • lung recruitment
No Intervention: Control
Preterm infants will be assisted in the delivery room with a continuous positive airway pressure (CPAP) of 5 cmH2O with mask and the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in Reactance (Xrs) values measured by the forced oscillation technique (FOT)
Time Frame: Baseline and at 5 minutes of life (that is, before and at the end of the SLI)
Baseline and at 5 minutes of life (that is, before and at the end of the SLI)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Need for intubation within the first 72 hours of life
Time Frame: 72 hours of life
72 hours of life
Duration of respiratory support (ventilation, CPAP, supplemental oxygen)
Time Frame: During hospitalization - up to 36 weeks Post Menstrual Age (PMA)
During hospitalization - up to 36 weeks Post Menstrual Age (PMA)
Death in hospital
Time Frame: During hospitalization - up to 40 weeks Post Menstrual Age (PMA)
During hospitalization - up to 40 weeks Post Menstrual Age (PMA)
Number of surfactant doses
Time Frame: During hospitalization - up to 36 weeks Post Menstrual Age (PMA)
During hospitalization - up to 36 weeks Post Menstrual Age (PMA)
Retinopathy of prematurity (ROP) stage 3 or greater requiring treatment
Time Frame: 40 weeks Post Menstrual Age (PMA)
40 weeks Post Menstrual Age (PMA)
Incidence of Patent Ductus Arteriosus (PDA) requiring treatment
Time Frame: During hospitalization - up to 36 weeks Post Menstrual Age (PMA)
During hospitalization - up to 36 weeks Post Menstrual Age (PMA)
Incidence of Bronchopulmonary dysplasia
Time Frame: 36 weeks Post Menstrual Age (PMA)
Defined according to the criteria of Jobe and Bancalari (Jobe A, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-9)
36 weeks Post Menstrual Age (PMA)
Incidence of Intracranial Hemorrhages (ICH)
Time Frame: During hospitalization- up to 40 weeks Post Menstrual Age (PMA)
We used the ICH classification of Papile et al
During hospitalization- up to 40 weeks Post Menstrual Age (PMA)
Length of hospital stay
Time Frame: Average discharge between 36 - 40 weeks PMA
Average discharge between 36 - 40 weeks PMA

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mariarosa Colnaghi, MD, NICU, IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

March 1, 2016

Primary Completion (Anticipated)

March 1, 2017

Study Completion (Anticipated)

March 1, 2018

Study Registration Dates

First Submitted

June 23, 2015

First Submitted That Met QC Criteria

July 9, 2015

First Posted (Estimate)

July 10, 2015

Study Record Updates

Last Update Posted (Actual)

March 2, 2021

Last Update Submitted That Met QC Criteria

February 26, 2021

Last Verified

February 1, 2021

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Diseases

Clinical Trials on Sustained lung inflation

3
Subscribe